Physician profile
Julia Sein
NPI 1295178291
$4,962.77
in general payments reported to CMS, 2019-2025
20 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.91 · 2020: $44.21 · 2021: $325 · 2022: $501 · 2023: $3,180 · 2024: $177 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,950 · Food and Beverage: $1,106 · Entertainment: $23.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,950.00 |
| Food and Beverage | $1,105.57 |
| Entertainment | $23.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,950.00 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $374.82 | 2022-2025 | Eylea, Eylea Hd |
| Regeneron Healthcare Solutions, INC. | $364.89 | 2021-2023 | Eylea |
| Genentech USA, INC. | $315.59 | 2020-2025 | Vabysmo, Susvimo, Lucentis |
| Abbvie INC. | $171.16 | 2022-2025 | Ozurdex |
| Glaukos Corporation | $153.56 | 2024 | Ce-Marked Kxla System |
| Novo Nordisk INC | $125.03 | 2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $97.88 | 2021 | |
| Apellis Pharmaceuticals, INC. | $60.29 | 2023-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $50.56 | 2025 | Iluvien, Yutiq |
| Astellas Pharma US INC | $45.86 | 2025 | Izervay |
| Allergan, INC. | $38.84 | 2021 | |
| Eyepoint US, INC. | $37.44 | 2022 | |
| Biogen, INC. | $36.58 | 2022-2023 | |
| Alimera Sciences, INC. | $31.86 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.55 | 2021 | |
| Optos, INC. | $23.80 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $22.12 | 2025 | Xipere |
| Merck Sharp & Dohme LLC | $22.03 | 2025 | Bridion |
| Hoffmann-La Roche Limited | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Sein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.